After years of weight loss drug shortages, the FDA is saying there's now an adequate supply for most medications and they will be prohibiting like-for-like compounded versions.

The U.S. Food and Drug Administration said on Monday it will not take action against compounding pharmacies making copies of Novo Nordisk's weight-loss drug Wegovy until a federal court delivers its ruling in a lawsuit against the agency.

Most compounded versions of popular drugs used for weight loss including Wegovy and Zepbound may soon no longer be available after a U.S. judge declined an initial injunction to allow compounding pharmacies to continue making versions.

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available after a decision by the U.S. Food and Drug Administration. The agency has ordered compounding pharmacies to stop making compound versions of GLP-1 drugs now that the drugs are no longer in short supply.